Newly diagnosed Scottish patients will be offered Tasigna (nilotinib) see below:
Sandy
Advice
Following a full submission:
nilotinib 150mg hard capsules (Tasigna®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.
First-line treatment with nilotinib in newly diagnosed patients has resulted in significantly higher molecular and cytogenetic response rates compared to the standard tyrosine kinase inhibitor. Further longer term follow-up data are needed to confirm the duration of this response and assess the impact on disease progression and overall survival.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of nilotinib. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland
Drug Details
Drug Name:
nilotinib (Tasigna)
SMC Drug ID:
709/11
Manufacturer:
Novartis Pharmaceuticals UK Ltd
Indication:
For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.
BNF Category:
8. Malignant disease and immunosuppression
Sub Category:
8.1 Cytotoxic drugs
Submission Type:
Full submission
Status:
Accepted
Date Advice Published:
8 August 2011
http://www.scottishmedicines.org.uk/SMC_Advice/Advice/709_11_nilotinib_Tasigna/nilotinib_Tasigna
